AbCellera Biologics Inc (ABCL)

Etorro trading 970x250
AbCellera Biologics Inc (ABCL) Logo

About AbCellera Biologics Inc

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada. Address: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1

AbCellera Biologics Inc News and around…

Latest news about AbCellera Biologics Inc (ABCL) common stock and company :

Could The AbCellera Biologics Inc. (NASDAQ:ABCL) Ownership Structure Tell Us Something Useful?
16 Oct, 2021 Yahoo! Finance

The big shareholder groups in AbCellera Biologics Inc. ( NASDAQ:ABCL ) have power over the company. Insiders often own...

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
14 Oct, 2021 FinancialContent

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

Harvard University Stock Portfolio: Top 10 Picks
11 Oct, 2021 Yahoo! Finance

In this article, we discuss the top 10 picks in Harvard University’s stock portfolio. You can skip our detailed analysis of the Harvard Management Company’s past performance and go directly to Harvard University Stock Portfolio: Top 5 Picks. Harvard’s endowment is Harvard University’s largest financial asset and comprises over 14,000 funds. The endowment is managed […]

Why AbCellera Biologics Stock Jumped 19.4% Last Month
07 Oct, 2021 FinancialContent

Despite last month's gains, the biotech stock is now down roughly 61% year to date.

AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic Antibodies
23 Sep, 2021 FinancialContent

AbCellera Biologics Inc(NASDAQ: ABCL) andEverest Medicines Limitedhaveentered into a multi-year collaboration ...

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Cramer's Advice On Ulta Beauty, Laredo Petroleum And More
23 Sep, 2021 FinancialContent

On CNBC's "Mad Money Lightning Round," Jim Cramer advised a viewer to buy more Ulta Beauty Inc (NASDAQ: ULTA). He likes ...

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
22 Sep, 2021 FinancialContent

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

A Day Of Huge Market Moves
21 Sep, 2021 FinancialContent

It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority. 

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
21 Sep, 2021 FinancialContent

Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

Best Biotech Stocks To Buy Now? 4 For Your Watchlist
18 Sep, 2021 FinancialContent
FDA’s Call on Lilly’s Covid Drug Is Lifting a Partner’s Beaten-Down Stock
17 Sep, 2021 Yahoo! Finance

The agency is allowing Lilly's product to be used as a prophylaxis in people who have been exposed to the virus.

Stock Market News For Today September 17, 2021
17 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
17 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips There's only one day of trading left so let's start it off right with a look at the biggest pre-market stock movers for Friday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

15 Stocks Moving in Friday's Pre-Market Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ...

AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
17 Sep, 2021 FinancialContent

TheFDA has expanded the Emergency Use Authorization(EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered ...

Premarket Movers Friday - Take-Two, Lucid, Invesco, AbCellera
17 Sep, 2021 Yahoo! Finance

Stocks moving in premarket trading Friday include Take-Two Interactive, Invesco, Lucid, Manchester United and AbCellera.

Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
16 Sep, 2021 FinancialContent

EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

AbCellera, Kymera and Diamondback Move in After-Hours
16 Sep, 2021 Yahoo! Finance

Among stocks seeing big moves in after-hours trading Thursday, AbCellera Biologics gained after saying it won emergency use authorization from the Food and Drug Administration for a treatment of people who've been exposed to COVID. The company said its bamlanivimab drug can now be used in combination with another drug called etesevimab "to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination." The move "provides a way to protect the significant number of people who, because of their situational exposure risk or medical condition, remain vulnerable to COVID-19," said Carl Hansen, CEO and president of AbCellera, in a statement.

Why AbCellera Biologics Stock Jumped 7% on Wednesday
15 Sep, 2021 FinancialContent

The company's drug-development technology is starting to attract attention.

AbCellera Shares Are Moving Higher On Licensing Pact With Moderna
15 Sep, 2021 FinancialContent

AbCellera Biologics Inc(NASDAQ: ABCL) has entered into aresearch collaboration and license ...

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
15 Sep, 2021 FinancialContent

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
13 Sep, 2021 FinancialContent

AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
10 Sep, 2021 FinancialContent

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

A Weak Week
10 Sep, 2021 FinancialContent

Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants.

Here's Why AbCellera Biologics Stock Gained 10.6% Last Month
04 Sep, 2021 FinancialContent

Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.

ABCL Trading 5.7% Below Director's Recent Buy Price
23 Aug, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on August 16, AbCellera Biologics Inc's Director, John S..

Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics
18 Aug, 2021 FinancialContent

Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics

Analysts Are More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) Than They Used To Be
17 Aug, 2021 Yahoo! Finance

The analysts covering AbCellera Biologics Inc. ( NASDAQ:ABCL ) delivered a dose of negativity to shareholders today, by...

AbCellera Biologics Inc (ABCL) is a NASDAQ Common Stock listed in , ,

970x250